Bruker BioSciences to Host Investor Booth Tour at Pittcon 2006

Bruker BioSciences announces its annual new product
booth tour for institutional investors and analysts at Pittcon 2006 in
Orlando, Florida. The investor tour will start promptly on Tuesday,
March 14 at 10 a.m. Eastern Time at the Company's booth #3155, and
will last approximately 45 minutes. To participate, please RSVP to
[e-mail].
   Bruker BioSciences expects to introduce a host of innovative
systems and solutions for life science and advanced materials
research. Novel product introductions will include Bruker AXS' unique
QUANTAX(TM) QUAD, an innovative EDS system for X-ray microanalysis on
electron microscopes, as well as Bruker Daltonics' novel MALDI
Biotyper(TM) system for the identification and classification of
microorganisms from protein profiles measured by MALDI-TOF mass
spectrometry.
   Pittcon 2006, the 57th Pittsburgh Conference and Exposition on
Analytical Chemistry and Applied Spectroscopy, is being held from
March 13-16 in Orlando, Florida in the Orange County Convention
Center. Bruker BioSciences will exhibit at booth #3155.

   ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)

   Bruker BioSciences Corporation, headquartered in Billerica,
Massachusetts, is the publicly traded parent company of Bruker AXS
Inc. and Bruker Daltonics Inc. Bruker AXS is a leading developer and
provider of life science, materials research and industrial X-ray
analysis tools. Bruker Daltonics is a leading developer and provider
of innovative life science tools based on mass spectrometry. For more
information, please visit www.bruker-biosciences.com

   CAUTIONARY STATEMENT

   Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements as
that term is defined in the Private Securities Litigation Reform Act
of 1995. Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results to
differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
reorganization strategies, integration risks, failure of conditions,
technological approaches, product development, market acceptance, cost
and pricing of the Company's products, changes in governmental
regulations, capital spending and government funding policies, FDA and
other regulatory approvals to the extent applicable, competition, the
intellectual property of others, patent protection and litigation.
These and other factors are identified and described in more detail in
our filings with the SEC, including, without limitation, our
respective annual reports on Form 10-K for the year ended December 31,
2004, our most recent quarterly reports on Form 10-Q, and our current
reports on Form 8-K. We disclaim any intent or obligation to update
these forward-looking statements.